| abstract |
The present invention includes, but is not limited to, Lewy bodies and / or Lewy neuropathy, alpha-synuclein (α-synuclein, A-synuclein, a-synuclein, a-synuclein, A-syn, α-syn). , ASyn, SNCA, non-amyloid beta component of amyloid plaques in Alzheimer's disease (AD), non-A4 component of amyloid precursors, a group of disorders and abnormalities associated with NACP) aggregates, such as Parkinson's disease (PD). , With respect to novel compounds that can be employed in monitoring disease progression or drug activity. The compounds are particularly useful in diagnosing the preclinical status of such disorders, monitoring residual disorders, or predicting the responsiveness of patients suffering from such disorders to treatment with certain medications. |